Amylyx Pharmaceuticals (AMLX) Operating Income: 2021-2025
Historic Operating Income for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Sep 2025 value amounting to -$36.0 million.
- Amylyx Pharmaceuticals' Operating Income rose 52.38% to -$36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$157.3 million, marking a year-over-year increase of 42.18%. This contributed to the annual value of -$314.7 million for FY2024, which is 911.12% down from last year.
- Per Amylyx Pharmaceuticals' latest filing, its Operating Income stood at -$36.0 million for Q3 2025, which was up 15.94% from -$42.9 million recorded in Q2 2025.
- Over the past 5 years, Amylyx Pharmaceuticals' Operating Income peaked at $20.2 million during Q2 2023, and registered a low of -$122.1 million during Q1 2024.
- Over the past 3 years, Amylyx Pharmaceuticals' median Operating Income value was -$37.8 million (recorded in 2025), while the average stood at -$35.7 million.
- Per our database at Business Quant, Amylyx Pharmaceuticals' Operating Income spiked by 137.23% in 2023 and then slumped by 5,848.86% in 2024.
- Quarterly analysis of 5 years shows Amylyx Pharmaceuticals' Operating Income stood at -$28.3 million in 2021, then plummeted by 57.49% to -$44.6 million in 2022, then surged by 104.34% to $1.9 million in 2023, then plummeted by 2,202.07% to -$40.7 million in 2024, then soared by 52.38% to -$36.0 million in 2025.
- Its Operating Income stands at -$36.0 million for Q3 2025, versus -$42.9 million for Q2 2025 and -$37.8 million for Q1 2025.